Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector
- 1 May 2004
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 18 (8) , 1213-1216
- https://doi.org/10.1097/00002030-200405210-00019
Abstract
The seroprevalence of adenovirus types 5 (Ad5) and 35 (Ad35) was investigated in patients at risk of AIDS. The seroprevalence of Ad5 was higher than Ad35 in HIV-infected patients from The Netherlands (60% versus 7%) and sub-Saharan Africa (90% versus 20%). The seroprevalence was similar among HIV-infected and uninfected individuals, and remained constant during progression to AIDS. Ad35 is less prone to neutralization than Ad5, encouraging the further development of Ad35 for vaccination against HIV.Keywords
This publication has 11 references indexed in Scilit:
- Development of adenovirus serotype 35 as a gene transfer vectorVirology, 2003
- Efficient gene transfer into human CD34+ cells by an adenovirus type 35 vectorGene Therapy, 2003
- Overcoming Immunity to a Viral Vaccine by DNA Priming before Vector BoostingJournal of Virology, 2003
- Exploiting the Natural Diversity in Adenovirus Tropism for Therapy and Prevention of DiseaseJournal of Virology, 2002
- Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunityNature, 2002
- Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigenProceedings of the National Academy of Sciences, 2001
- Improved Adenovirus Vectors for Infection of Cardiovascular TissuesJournal of Virology, 2001
- Development of a preventive vaccine for Ebola virus infection in primatesNature, 2000
- New Helper Cells and Matched Early Region 1-Deleted Adenovirus Vectors Prevent Generation of Replication-Competent AdenovirusesHuman Gene Therapy, 1998
- ADENOVIRUS ISOLATES FROM URINE OF PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYNDROMEThe Lancet, 1983